Skip to main content
Top
Published in: Clinical Rheumatology 3/2016

01-03-2016 | Original Article

Evaluation of serum procalcitonin and C-reactive protein levels as biomarkers of Henoch-Schönlein purpura in pediatric patients

Authors: Xu Teng, Yang Wang, Nan Lin, Mei Sun, Jie Wu

Published in: Clinical Rheumatology | Issue 3/2016

Login to get access

Abstract

Henoch-Schönlein purpura (HSP) is a vasculitic disorder resulting from autoinflammatory-mediated tissue injury. Procalcitonin (PCT) and C-reactive protein (CRP) are two biomarkers of the immune response that recognize bacterial infection and inflammation, respectively. This study tested whether levels of PCT and CRP were associated with selected clinical features, disease severity, and organ damage in HSP. Eighty-nine pediatric patients with HSP were analyzed for clinical manifestations and organ damage. Serum CRP, PCT, and occult blood in the urine and stool (prior to steroid therapy) were measured. Disease severity was classified according to previously established clinical classifications. Sixty patients (67.4 %) had a low clinical score (LCS) of <4 (group A) while 29 patients (32.5 %) had a high clinical score (HCS) of ≥4 (group B). When patients were then classified by the presence of gastrointestinal bleeding, 66 (74.2 %) cases lacked alimentary tract hemorrhage (group C) while 23 (25.8 %) cases presented with gastrointestinal bleeding (group D). There were no significant differences in CRP (group A: median = 5.26, range = 1.00–77.60 vs. group B: median = 8.59, range = 1.00–144.00 mg/l; u = 1.397) or PCT levels (group A: median = 0.05, range = 0.05–0.24 vs. group B: median = 0.08, range = 0.05–1.02 ng/ml; u = 1.709) between groups A and B. When serum PCT levels were examined in relation to gastrointestinal bleeding, the levels of serum PCT were higher in group D than group C patients (group D: median = 0.09, range = 0.05–1.02 vs. group C: median = 0.05, range = 0.05–0.32 ng/ml; u = 2.849). It is important to note that the average PCT level was below the threshold for a systemic bacterial infection (0.5 ng/ml). We did not observe a correlation between CRP levels and the absence or presence of GI bleeding in groups C or D (group C: median = 4.66, range = 1.00–144.00 vs. group D: median = 9.44, range = 1.06–124.00 mg/l; u = 1.783), respectively. In all patients, there was a significant correlation between the concentrations of PCT and CRP (r = 0.721, p = 0.002). In patients with HSP, inflammatory markers are not uniformly associated with the disease and instead, show variable association depending on the clinical severity and level of organ damage. In patients with severe HSP, elevated serum PCT was significantly associated with gastrointestinal bleeding. In contrast, CRP was not a specific predictor for different clinical classifications of HSP, despite a similar pattern of concentration changes to PCT.
Literature
1.
go back to reference Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR (2002) Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360(9341):1197–1202CrossRefPubMed Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR (2002) Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360(9341):1197–1202CrossRefPubMed
2.
go back to reference Bressan S, Gomez B, Mintegi S, Da Dalt L, Blazquez D, Olaciregui I, de la Torre M, Palacios M, Berlese P, Ruano A (2012) Diagnostic performance of the lab-score in predicting severe and invasive bacterial infections in well-appearing young febrile infants. Pediatr Infect Dis J 31(12):1239–1244CrossRefPubMed Bressan S, Gomez B, Mintegi S, Da Dalt L, Blazquez D, Olaciregui I, de la Torre M, Palacios M, Berlese P, Ruano A (2012) Diagnostic performance of the lab-score in predicting severe and invasive bacterial infections in well-appearing young febrile infants. Pediatr Infect Dis J 31(12):1239–1244CrossRefPubMed
3.
go back to reference Becker KL, Snider R, Nylen ES (2008) Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 36(3):941–952CrossRefPubMed Becker KL, Snider R, Nylen ES (2008) Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 36(3):941–952CrossRefPubMed
4.
go back to reference Schützle H, Forster J, Superti-Furga A, Berner R (2009) Is serum procalcitonin a reliable diagnostic marker in children with acute respiratory tract infections? A retrospective analysis. Eur J Pediatr 168(9):1117–1124CrossRefPubMed Schützle H, Forster J, Superti-Furga A, Berner R (2009) Is serum procalcitonin a reliable diagnostic marker in children with acute respiratory tract infections? A retrospective analysis. Eur J Pediatr 168(9):1117–1124CrossRefPubMed
5.
go back to reference Cevey-Macherel M, Galetto-Lacour A, Gervaix A, Siegrist CA, Bille J, Bescher-Ninet B, Kaiser L, Krahenbuhl JD, Gehri M (2009) Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. Eur J Pediatr 168(12):1429–1436CrossRefPubMed Cevey-Macherel M, Galetto-Lacour A, Gervaix A, Siegrist CA, Bille J, Bescher-Ninet B, Kaiser L, Krahenbuhl JD, Gehri M (2009) Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. Eur J Pediatr 168(12):1429–1436CrossRefPubMed
6.
go back to reference Makay B, Turkyilmaz Z, Duman M, Unsal E (2009) Mean platelet volume in Henoch-Schonlein purpura: relationship to gastrointestinal bleeding. Clin Rheumatol 28(10):1225–1228CrossRefPubMed Makay B, Turkyilmaz Z, Duman M, Unsal E (2009) Mean platelet volume in Henoch-Schonlein purpura: relationship to gastrointestinal bleeding. Clin Rheumatol 28(10):1225–1228CrossRefPubMed
7.
go back to reference Delevaux I, Andre M, Colombier M, Albuisson E, Meylheuc F, Begue RJ, Piette JC, Aumaitre O (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 62(4):337–340CrossRefPubMedPubMedCentral Delevaux I, Andre M, Colombier M, Albuisson E, Meylheuc F, Begue RJ, Piette JC, Aumaitre O (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 62(4):337–340CrossRefPubMedPubMedCentral
8.
go back to reference Volanakis JE (2001) Human C-reactive protein: expression, structure, and function. Mol Immunol 38(2–3):189–197CrossRefPubMed Volanakis JE (2001) Human C-reactive protein: expression, structure, and function. Mol Immunol 38(2–3):189–197CrossRefPubMed
9.
go back to reference Kasperska-Zajac A, Sztylc J, Machura E, Jop G (2011) Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy 41(10):1386–1391CrossRefPubMed Kasperska-Zajac A, Sztylc J, Machura E, Jop G (2011) Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy 41(10):1386–1391CrossRefPubMed
10.
go back to reference Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P (2006) EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 65(7):936–941CrossRefPubMedPubMedCentral Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P (2006) EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 65(7):936–941CrossRefPubMedPubMedCentral
11.
go back to reference De Mattia D, Penza R, Giordano P, Del Vecchio GC, Aceto G, Altomare M, Schettini F (1995) von Willebrand factor and factor XIII in children with Henoch-Schonlein purpura. Pediatr Nephrol 9(5):603–605CrossRefPubMed De Mattia D, Penza R, Giordano P, Del Vecchio GC, Aceto G, Altomare M, Schettini F (1995) von Willebrand factor and factor XIII in children with Henoch-Schonlein purpura. Pediatr Nephrol 9(5):603–605CrossRefPubMed
12.
go back to reference Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, Kushimoto S, Yukioka H, Kato N, Totsuka K, Kikuchi K, Ikeda T, Ikeda K, Harada K, Satomura S (2005) Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 11(3):152–159CrossRefPubMed Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, Kushimoto S, Yukioka H, Kato N, Totsuka K, Kikuchi K, Ikeda T, Ikeda K, Harada K, Satomura S (2005) Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 11(3):152–159CrossRefPubMed
13.
go back to reference Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R (1997) Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 40(7):1250–1256CrossRefPubMed Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R (1997) Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 40(7):1250–1256CrossRefPubMed
14.
go back to reference Maier M, Wutzler S, Lehnert M, Szermutzky M, Wyen H, Bingold T, Henrich D, Walcher F, Marzi I (2009) Serum procalcitonin levels in patients with multiple injuries including visceral trauma. J Trauma 66(1):243–249CrossRefPubMed Maier M, Wutzler S, Lehnert M, Szermutzky M, Wyen H, Bingold T, Henrich D, Walcher F, Marzi I (2009) Serum procalcitonin levels in patients with multiple injuries including visceral trauma. J Trauma 66(1):243–249CrossRefPubMed
15.
go back to reference Lanoix JP, Bourgeois AM, Schmidt J, Desblache J, Salle V, Smail A, Maziere JC, Betsou F, Choukroun G, Duhaut P, Ducroix JP (2011) Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 20(2):125–130CrossRefPubMed Lanoix JP, Bourgeois AM, Schmidt J, Desblache J, Salle V, Smail A, Maziere JC, Betsou F, Choukroun G, Duhaut P, Ducroix JP (2011) Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 20(2):125–130CrossRefPubMed
16.
go back to reference Meisner M, Adina H, Schmidt J (2006) Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care 10(1):R1CrossRefPubMedPubMedCentral Meisner M, Adina H, Schmidt J (2006) Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care 10(1):R1CrossRefPubMedPubMedCentral
17.
go back to reference Okada Y, Minakami H, Tomomasa T, Kato M, Inoue Y, Kozawa K, Kimura H, Morikawa A (2004) Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 48(2):199–205CrossRefPubMed Okada Y, Minakami H, Tomomasa T, Kato M, Inoue Y, Kozawa K, Kimura H, Morikawa A (2004) Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 48(2):199–205CrossRefPubMed
18.
go back to reference Yoshikawa H, Nomura Y, Masuda K, Koriya C, Arata M, Hazeki D, Yanagimoto K, Ueno K, Eguchi T, Kawano Y (2012) Serum procalcitonin value is useful for predicting severity of Kawasaki disease. Pediatr Infect Dis J 31(5):523–525CrossRefPubMed Yoshikawa H, Nomura Y, Masuda K, Koriya C, Arata M, Hazeki D, Yanagimoto K, Ueno K, Eguchi T, Kawano Y (2012) Serum procalcitonin value is useful for predicting severity of Kawasaki disease. Pediatr Infect Dis J 31(5):523–525CrossRefPubMed
19.
go back to reference Chen DY, Chen YM, Ho WL, Chen HH, Shen GH, Lan JL (2009) Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis 68(6):1074–1075CrossRefPubMed Chen DY, Chen YM, Ho WL, Chen HH, Shen GH, Lan JL (2009) Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis 68(6):1074–1075CrossRefPubMed
20.
go back to reference Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34(7):1996–2003CrossRefPubMed Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34(7):1996–2003CrossRefPubMed
21.
go back to reference Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, Reinhart K (1999) Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med 37(8):789–797CrossRefPubMed Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, Reinhart K (1999) Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med 37(8):789–797CrossRefPubMed
22.
go back to reference Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, Snitker S, Horenstein RB, Hull K, Goldberg NH, Goldberg AP, Shuldiner AR, Fried SK, Gong DW (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 3(6):e287CrossRefPubMedPubMedCentral Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, Snitker S, Horenstein RB, Hull K, Goldberg NH, Goldberg AP, Shuldiner AR, Fried SK, Gong DW (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 3(6):e287CrossRefPubMedPubMedCentral
23.
go back to reference Ha TS (2005) The role of tumor necrosis factor-alpha in Henoch-Schonlein purpura. Pediatr Nephrol 20(2):149–153CrossRefPubMed Ha TS (2005) The role of tumor necrosis factor-alpha in Henoch-Schonlein purpura. Pediatr Nephrol 20(2):149–153CrossRefPubMed
24.
go back to reference Yang YH, Lai HJ, Huang CM, Wang LC, Lin YT, Chiang BL (2004) Sera from children with active Henoch-Schonlein purpura can enhance the production of interleukin 8 by human umbilical venous endothelial cells. Ann Rheum Dis 63(11):1511–1513CrossRefPubMedPubMedCentral Yang YH, Lai HJ, Huang CM, Wang LC, Lin YT, Chiang BL (2004) Sera from children with active Henoch-Schonlein purpura can enhance the production of interleukin 8 by human umbilical venous endothelial cells. Ann Rheum Dis 63(11):1511–1513CrossRefPubMedPubMedCentral
Metadata
Title
Evaluation of serum procalcitonin and C-reactive protein levels as biomarkers of Henoch-Schönlein purpura in pediatric patients
Authors
Xu Teng
Yang Wang
Nan Lin
Mei Sun
Jie Wu
Publication date
01-03-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2773-1

Other articles of this Issue 3/2016

Clinical Rheumatology 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.